Detection of circulating hepatitis B virus immune escape and polymerase mutants among HBV-positive patients attending Institut Pasteur de Bangui, Central African Republic.
Adolescent
Adult
Base Sequence
Central African Republic
/ epidemiology
DNA-Directed DNA Polymerase
/ genetics
Female
Genotype
Hepatitis B
/ blood
Hepatitis B Surface Antigens
/ blood
Hepatitis B virus
/ classification
Humans
Male
Middle Aged
Mutation
Phylogeny
Polymerase Chain Reaction
Viral Proteins
/ genetics
Young Adult
Central African Republic
Genotype/subgenotype
Hepatitis B virus
Immune escape mutants (IEMs)
Polymerase mutants
Serotype
Journal
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
ISSN: 1878-3511
Titre abrégé: Int J Infect Dis
Pays: Canada
ID NLM: 9610933
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
received:
02
10
2019
revised:
25
10
2019
accepted:
27
10
2019
pubmed:
5
11
2019
medline:
24
3
2020
entrez:
5
11
2019
Statut:
ppublish
Résumé
Previous studies in the Central African Republic (CAR) have reported the presence of hepatitis B virus (HBV) recombinant genotype E/D and a suspicion of immune escape mutants (IEMs), without further investigation into their impact on prevention and diagnosis. Consequently, this study investigated HBV mutations among hepatitis B surface antigen (HBsAg)-positive patients attending Institut Pasteur de Bangui in the CAR. Sera from a total of 118 HBsAg-positive patients with no previous history of HBV treatment or vaccination at the Institut Pasteur de Bangui, were sampled between 2017 and 2019. Subsequently, the region spanning the surface and polymerase genes of HBV was amplified by PCR and sequenced. HBV sequences were genotyped/subgenotyped by phylogenetic analysis and serotyped based on predicted amino acid residues at positions s122, s127, s140, s159, and s160. They were then analyzed for HBV IEMs and polymerase mutations. The region spanning the surface and polymerase genes was successfully amplified and sequenced for 51 samples. Of the HBV sequences, 49 were genotype E and two were genotype A subgenotype A1; these were serotyped as ayw4 and ayw1, respectively. Potential IEMs sY100C, sA128V, and sM133T, and several polymerase mutants were identified. This study raises awareness of the need for further studies to be conducted on a large scale to better understand HBV mutations for improved disease control and prevention strategies in the country.
Sections du résumé
BACKGROUND
BACKGROUND
Previous studies in the Central African Republic (CAR) have reported the presence of hepatitis B virus (HBV) recombinant genotype E/D and a suspicion of immune escape mutants (IEMs), without further investigation into their impact on prevention and diagnosis. Consequently, this study investigated HBV mutations among hepatitis B surface antigen (HBsAg)-positive patients attending Institut Pasteur de Bangui in the CAR.
METHODS
METHODS
Sera from a total of 118 HBsAg-positive patients with no previous history of HBV treatment or vaccination at the Institut Pasteur de Bangui, were sampled between 2017 and 2019. Subsequently, the region spanning the surface and polymerase genes of HBV was amplified by PCR and sequenced. HBV sequences were genotyped/subgenotyped by phylogenetic analysis and serotyped based on predicted amino acid residues at positions s122, s127, s140, s159, and s160. They were then analyzed for HBV IEMs and polymerase mutations.
RESULTS
RESULTS
The region spanning the surface and polymerase genes was successfully amplified and sequenced for 51 samples. Of the HBV sequences, 49 were genotype E and two were genotype A subgenotype A1; these were serotyped as ayw4 and ayw1, respectively. Potential IEMs sY100C, sA128V, and sM133T, and several polymerase mutants were identified.
CONCLUSIONS
CONCLUSIONS
This study raises awareness of the need for further studies to be conducted on a large scale to better understand HBV mutations for improved disease control and prevention strategies in the country.
Identifiants
pubmed: 31682960
pii: S1201-9712(19)30433-3
doi: 10.1016/j.ijid.2019.10.039
pmc: PMC6912157
pii:
doi:
Substances chimiques
Hepatitis B Surface Antigens
0
Viral Proteins
0
DNA-Directed DNA Polymerase
EC 2.7.7.7
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
138-144Informations de copyright
Copyright © 2019 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Références
Hepat Mon. 2010 Spring;10(2):141-6
pubmed: 22312387
PLoS Negl Trop Dis. 2018 Aug 6;12(8):e0006629
pubmed: 30080852
Jpn J Infect Dis. 2017 Nov 22;70(6):647-655
pubmed: 29093313
Virol J. 2007 Sep 24;4:92
pubmed: 17892576
World J Gastroenterol. 2014 Jun 28;20(24):7653-64
pubmed: 24976703
Aliment Pharmacol Ther. 2009 Dec 1;30(11-12):1150-8
pubmed: 19785624
BMC Infect Dis. 2013 Jun 24;13:286
pubmed: 23800310
Int J Epidemiol. 2005 Dec;34(6):1329-39
pubmed: 16249217
J Virol. 2013 Feb;87(4):2352-7
pubmed: 23221548
PLoS One. 2018 Feb 6;13(2):e0191970
pubmed: 29408943
J Virol Methods. 1991 Jun;33(1-2):27-38
pubmed: 1939511
Intervirology. 2014;57(3-4):141-50
pubmed: 25034481
Mol Biol Evol. 2018 Jun 1;35(6):1547-1549
pubmed: 29722887
PeerJ. 2019 Mar 8;7:e6583
pubmed: 30867996
J Virol. 2010 Dec;84(24):12850-61
pubmed: 20881037
PLoS One. 2017 Dec 7;12(12):e0188944
pubmed: 29216251
World J Hepatol. 2015 May 28;7(9):1282-6
pubmed: 26019744
Antivir Ther. 2015;20(4):387-95
pubmed: 25624410
Genes (Basel). 2018 Sep 27;9(10):
pubmed: 30262738
PLoS One. 2014 Dec 12;9(12):e113821
pubmed: 25503289
J Clin Virol. 2007 Sep;40(1):31-7
pubmed: 17689139
Viruses. 2015 Feb 16;7(2):781-97
pubmed: 25690798
World J Gastroenterol. 2017 Jun 21;23(23):4222-4232
pubmed: 28694662
PLoS Negl Trop Dis. 2018 Apr 26;12(4):e0006377
pubmed: 29698488
J Med Virol. 2018 Oct;90(10):1576-1585
pubmed: 29797607
Clin Transplant. 2003 Dec;17(6):554-9
pubmed: 14756274
Hepat Res Treat. 2011;2011:695859
pubmed: 21331286
J Gastroenterol Hepatol. 2011 Jan;26 Suppl 1:123-30
pubmed: 21199523
Acta Virol. 2018;62(2):115-121
pubmed: 29895151
Hepatol Int. 2008 Jun;2(2):147-51
pubmed: 19669299
Hepatology. 1998 Jan;27(1):254-63
pubmed: 9425945
J Clin Virol. 2010 Feb;47(2):193-5
pubmed: 20031483
World J Gastroenterol. 2018 Apr 28;24(16):1708-1724
pubmed: 29713126
ScientificWorldJournal. 2013 Nov 26;2013:571875
pubmed: 24379746
J Gen Virol. 2006 May;87(Pt 5):1163-73
pubmed: 16603517
J Med Virol. 2008 Jan;80(1):27-46
pubmed: 18041043
Infect Drug Resist. 2017 Jul 05;10:201-207
pubmed: 28740410